Chiara Rodaro

Chiara Rodaro

Auto-generated profile, based on publicly available information

Chiara Rodaro

Clinical Department of Medical, Surgical and Health Science, University of Trieste, Trieste, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2025 in Annals of Pediatric Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
CRChiara Rodaro
Chiara Rodaro
GTGianluca Tamaro
Gianluca Tamaro
EFElena Faleschini
Elena Faleschini
GTGianluca Tornese
Gianluca Tornese
Long-acting growth hormones (LAGHs) represent a significant advancement in the treatment of pediatric GH deficiency, offering an alternative to daily recombinant human GH (rhGH) therapy. Traditional rhGH treatments, although effective, require daily injections, often leading to poor adherence due to the frequency of dosing, injection pain, and difficulties with storage and travel. In contrast, LAGHs, such as somatrogon, somapacitan, and lonapegsomatropin, are designed for once-weekly administration, improving patient compliance and quality of life. LAGHs have demonstrated non-inferiority to daily rhGHs in phase 3 clinical trials, showing similar efficacy in terms of growth velocity and safety profiles. Despite these advantages, concerns remain regarding the altered pharmacodynamics of LAGHs such as the lack of pulsatile secretion and potential for antibody formation. Although the overall safety of LAGHs has been confirmed, side effects, such as lipoatrophy at the injection site, may occur, especially with PEGylated formulations. Guidelines for prescribing LAGHs are currently evolving. LAGHs are not yet approved for other conditions traditionally treated with rhGHs, such as Turner or Noonan syndrome. Pediatric endocrinologists should carefully consider which patient groups would benefit most from this therapy, particularly individuals at risk of poor adherence to daily injections such as patients undergoing multidrug therapy, patients with needle phobia or behavioral disorders, very young children, adolescents, patients with separated parents, families that travel frequently, or children involved in activities such as scouting. LAGHs present an opportunity to enhance therapeutic outcomes and adherence, but careful patient selection remains critical to maximize their potential benefits.

1 January 2025 in Pediatric Gastroenterology, Hepatology & Nutrition
Verified
Journal Article
Open access
ASAndrea Di Siena
Andrea Di Siena
PMPaola Melli
Paola Melli
FRFederica Rodofile
Federica Rodofile
CRChiara Rodaro
Chiara Rodaro
MMMarco Marino
Marco Marino
PCPaola Cogo
Paola Cogo
Foreign body (FB) ingestion is a common health problem that affects children. It requires endoscopic removal in up to 20% of cases. In this study, we reviewed all our pediatric cases of FB ingestion requiring endoscopy and compared their management to the published guidelines. Retrospective study of children (aged 0–16 years) who were admitted to the emergency pediatric service department and underwent endoscopy for FB ingestion from January 2007 to December 2022. All statistical analyses were performed using STATA software version 17.0 (StataCorp LP). Of a total of 962 children diagnosed with FB ingestion, 62 of them (median age 4 years; interquartile range 2–8 years) underwent endoscopies and were included in this study. Of these, 39 (62.9%) were symptomatic and 23 (37.1%) were asymptomatic. The most common symptoms were vomiting (24.2%), pain (24.2%), sialorrhea (22.6%). In most patients, FBs were located in the esophagus (56.2%), with coins being the most common type (42.0%). The occurrence of at least one symptom was found to be associated with the FBs located in the upper-middle esophagus (compared to all other anatomical regions) (p<0.001). NASPGHAN and ESPGHAN guidelines were met in 68.8% of patients, while SIGENP guidelines were met in 72.9%. FB ingestion is common in children. Coins are the most frequently encountered objects, typically located in the esophagus or stomach. An association was observed between the presence of at least one symptom and FBs located in the upper-middle esophagus. Performing endoscopies within 2 hours of FB ingestion is challenging in some cases.

28 May 2026 in Endocrine
Verified
Journal Article
Open access
CRChiara Rodaro
Chiara Rodaro
GTGianluca Tamaro
Gianluca Tamaro
AFAlice Fachin
Alice Fachin
FNFrancesca Nicolardi
Francesca Nicolardi
STSilvia Tommasi
Silvia Tommasi
GTGianluca Tornese
Gianluca Tornese
Growth hormone deficiency (GHD) in childhood and adolescence requires long-term therapy with recombinant human growth hormone (rhGH). Although daily injections are highly effective, they impose a considerable treatment burden that often leads to suboptimal adherence and compromised growth outcomes. Reported non-adherence rates vary widely, largely due to heterogeneous definitions and assessment methods. Adherence is influenced by multiple factors, including device usability, psychosocial context, family engagement, and the level of support from health care professionals. Although Long-Acting Growth Hormone (LAGH) preparations, administered once weekly, have demonstrated efficacy and safety comparable to daily rhGH in clinical trials, adherence in these settings may be overestimated. The key question now is whether LAGH can truly enhance treatment adherence in real-world settings. This narrative review summarizes the very limited data currently available on adherence to LAGH in both treatment-naïve patients and those switching from daily rhGH, highlighting methodological heterogeneity and the absence of robust long-term outcomes. Rather than providing definitive conclusions, our aim is to map existing evidence, identify critical gaps, and outline priorities for future real-world and longitudinal studies evaluating adherence, persistence, and clinical consequences of poor adherence in LAGH users.

18 January 2026 in Molecular Genetics and Metabolism Reports
Verified
Journal Article
Open access
MFMaja Filipic
Maja Filipic
ŽRŽiga Iztok Remec
Žiga Iztok Remec
ATAna Drole Torkar
Ana Drole Torkar
NSNataša Sustar
Nataša Sustar
VCVanja Cuk
Vanja Cuk
BLBarbka Repic Lampret
Barbka Repic Lampret
Branched-chain amino acid transaminase 2 (BCAT2) deficiency is an autosomal recessive disorder that impairs branched-chain amino acid (BCAA) catabolism. Its clinical and metabolic features remain poorly understood due to limited reports in the literature. We report three novel cases of BCAT2 deficiency from Slovenia: one diagnosed following symptom onset, one through cascade screening of parents, and one by newborn screening. Diagnosis was established through metabolic evaluation and confirmation of pathogenic variants in the BCAT2 gene. In addition, we performed a systematic review of all previously reported cases of BCAT2 deficiency. All three patients were homozygous for the NM_001190.4:c.600C > A (p.Tyr200Ter) variant, with valine concentrations at presentation of 2093, 2589, and 794 μmol/L. Only one patient was symptomatic, presenting with headaches, developmental delay, and intellectual disability, while the remaining two were largely asymptomatic. Notably, insulin resistance was observed in one of the three patients and may be associated with elevated BCAA levels. Systematic literature review identified 8 additional cases of BCAT2 deficiency. Genetic variant c.600C > A was also found in two Pakistani individuals, while the remaining variants were each reported in only a single individual. The most common clinical characteristics were intellectual disability (55%), developmental delay and other neurological symptoms (36%). Abnormal white matter findings on MRI were observed in all patients who underwent imaging. BCAA levels decreased in all patients receiving pyridoxine supplementation; however, only 50% showed clinical improvement. BCAT2 deficiency displays marked interindividual heterogeneity, ranging from asymptomatic cases to severe neurological impairment, which renders its pathogenicity uncertain.

15 May 2026 in Medico e Bambino
Verified
Journal Article
Closed access
CRChiara Rodaro
Chiara Rodaro
FBFrancesco Baldo
Francesco Baldo
Lateralised overgrowth is a clinical entity that paediatricians need to know because it may suggest the presence of genetic syndromes with increased cancer risk. The paper presents two clinical cases of patients with lateralised overgrowth. It then replies to some questions that either the paediatrician or the family of the child might pose and aims to clarify the importance of ensuring appropriate follow-up care.

23 March 2025 in Archives of Disease in Childhood - Education & Practice Edition
Verified
Journal Article
Closed access
PDF file
CRChiara Rodaro
Chiara Rodaro
FCFederica Corona
Federica Corona
VCViola Ceconi
Viola Ceconi
ATAndrea Taddio
Andrea Taddio
ECElisabetta Cattaruzzi
Elisabetta Cattaruzzi
EBEgidio Barbi
Egidio Barbi
Blood tests showed an increased CRP of 12.1 mg/L and ESR of 75 mm/hour, but normal FBC, electrolytes and creatinine. An X-ray of the cervical spine was normal. The neck ultrasound showed small bilateral posterior cervical lymph nodes. An MRI was performed (see figures 1 and 2).